Financial Performance - The company incurred net losses of $204.6 million, $217.9 million, and $152.1 million for the years ended September 30, 2023, 2022, and 2021, respectively, with an accumulated deficit of $1,033.0 million as of September 30, 2023[142]. - The net loss attributable to common stockholders for 2023 was $204.6 million, compared to a net loss of $217.9 million in 2022, indicating a 6.0% improvement[438]. - The accumulated deficit increased to $1.033 billion as of September 30, 2023, compared to $828.4 million in 2022, reflecting a 24.7% increase[436]. - The company generated cash flows from operating activities amounting to a net cash used of $142.5 million, compared to $124.4 million in the previous year[446]. - Cash and cash equivalents decreased to $286.5 million as of September 30, 2023, down from $378.7 million in the previous year, representing a decline of 24.3%[436]. - The company's total operating expenses for 2023 were $462.3 million, up from $438.3 million in 2022, reflecting a 5.5% increase[438]. - The company reported interest income of $14.4 million in 2023, significantly higher than $3.1 million in 2022, marking a 370.6% increase[438]. - Twist Bioscience's total stockholders' equity decreased to $623.4 million in 2023 from $789.4 million in 2022, a decline of 21.0%[436]. - The company incurred stock-based compensation expenses of $30.3 million in 2023, down from $79.7 million in 2022[446]. - The company reported a net cash provided by investing activities of $50.6 million, a significant recovery from a net cash used of $232.9 million in the previous year[446]. Operational Challenges - The company expects to incur substantial losses and negative cash flow for the foreseeable future, influenced by factors such as market acceptance of products and inflationary pressures[142]. - A strategic restructuring plan announced on May 5, 2023, included a reduction in force affecting approximately 270 employees worldwide, which may not yield anticipated savings and could disrupt operations[147]. - The company relies on a single-source supplier for a critical component in its DNA synthesis process, and any disruption could adversely affect manufacturing capacity and revenue[142]. - The company faces challenges in expanding its DNA synthesis manufacturing capacity, which could impact revenue growth if customer demand increases[181]. - Any delays in securing raw materials or components could adversely affect production capabilities and financial performance[190]. - The company relies on third-party suppliers for critical components, which poses risks to its operational capabilities[454]. - The company is heavily reliant on the success of its synthetic DNA products, which have generated substantially all of its revenue to date[183]. - The company has invested significantly in research and development for synthetic DNA products, indicating a capital-intensive business model[182]. Market and Competitive Landscape - The company operates in a highly competitive industry with numerous competitors, which may lead to pricing pressures and adversely affect sales and profitability[206]. - The company’s business model is based on being the only provider of DNA synthesis on a silicon chip at a large commercial level, which could be disrupted if competitors develop similar technologies[167]. - The company’s revenue growth may depend on leveraging its DNA synthesis platform in adjacent markets, such as pharmaceutical biologics and digital data storage[170]. - A significant portion of the company’s sales depends on customers' research and development budgets, which can be subject to unexpected variations[171]. - The company generally does not have long-term contracts with customers, making it difficult to predict purchasing behavior[175]. - The loss of significant customers could adversely affect revenue and market reputation, as a substantial portion of revenue comes from a limited number of large customers[195]. Regulatory and Compliance Risks - The company is subject to the U.S. Foreign Corrupt Practices Act and the UK Anti-Bribery Act, which could result in civil or criminal penalties if violated, adversely affecting financial condition and growth prospects[201]. - The company is subject to strict regulatory controls on product exports, which could delay shipments and adversely affect revenues and profitability[215]. - The FDA's proposed rule on laboratory-developed tests could increase regulatory requirements, potentially influencing product sales and customer usage[217]. - Future products may be subject to additional FDA regulation, which could impose restrictions on marketing and sales, adversely affecting business operations[218]. - The company may incur significant costs to comply with the European Union's In Vitro Diagnostic Device Regulation (IVDR), which could adversely affect its business in the EU[219]. - The uncertainty from Brexit continues to pose risks that could adversely impact the company’s business and financial condition[178]. Intellectual Property and Legal Risks - The company’s ability to protect its intellectual property is uncertain, and failure to maintain such protection could adversely affect its competitive position[142]. - The company has faced challenges with patent applications, including an opposition to its European Patent No. 3030682 related to polynucleotide synthesis, which was initially decided to be revoked[243]. - Legal proceedings to enforce patent rights can be costly and time-consuming, potentially impacting the company's ability to market its products[256]. - The company may incur substantial costs related to royalty payments for licenses if it is found to infringe on third-party patents, negatively affecting gross margins[259]. - The complexity of collaboration arrangements may hinder the establishment of favorable agreements for licensing third-party intellectual property rights[265]. - The company may struggle to obtain necessary rights to products and technologies through acquisitions and in-licenses, impacting growth[264]. Future Outlook and Strategic Initiatives - The company plans to continue expanding its production capabilities and enter new markets, including COVID-19 testing products and pharmaceutical biologics drug discovery[143]. - The company aims to attract new customers and retain existing ones by delivering high-quality products and effective technical support, which is critical for growth[154]. - The company is pursuing strategic acquisitions to expand its product offerings in local and international markets, but faces risks associated with integration and financial resources[199]. - The company’s future success relies on its ability to develop and manufacture new products in the rapidly changing synthetic biology industry[165]. - The company may consider strategic transactions, including collaborations or investments, but faces significant operational and financial risks associated with such activities[200]. Cybersecurity and Operational Risks - The company has not experienced any material system failure or security breach to date, but ongoing cybersecurity threats could materially disrupt operations and financial condition[157]. - The company is at heightened risk of cyber attacks due to political uncertainty related to Russia's invasion of Ukraine, which could affect technology, data, and intellectual property[159]. - The company is vulnerable to natural disasters and public health crises that could disrupt operations and impair critical systems[223]. Stock and Market Risks - The market price of the company's common stock is likely to be volatile, influenced by various external factors beyond its control[285]. - The company has never paid dividends and does not intend to do so in the foreseeable future, relying on stock price appreciation for investor returns[275]. - Future sales and issuances of common stock could result in additional dilution for existing stockholders and potentially cause the stock price to decline[291]. - The company has been and may continue to be the target of short selling strategies that could drive down its stock price[290]. - The company's charter documents may prevent favorable takeover attempts, potentially reducing stock market value[276].

Financial Data and Key Metrics Changes - Revenue for Q4 2023 grew to $66.9 million, bringing total revenue for fiscal year 2023 to $245.1 million, representing a year-over-year growth of approximately 20% [9][64] - Gross margin for both the quarter and the year was approximately 37% [9][49] - Cash, cash equivalents, and investments at the end of the year totaled approximately $336 million [9][42] Business Line Data and Key Metrics Changes - NGS revenue for Q4 increased to approximately $37.1 million, a 27% year-over-year growth, with full-year revenue reaching $123.7 million, up 25% from the previous year [36] - SynBio revenue for Q4 was $26.5 million, totaling $98.2 million for fiscal 2023, up from $80 million in fiscal 2022 [37] - Biopharma revenue for Q4 was $3.4 million, totaling $23.2 million for fiscal 2023, a decline from $24.2 million in fiscal 2022 [38] Market Data and Key Metrics Changes - EMEA revenue rose to $71.4 million compared to $62.1 million in fiscal 2022, while APAC revenue increased to $22.5 million from $19.1 million [39] - U.S. revenue increased to $151.3 million in fiscal 2023 from $122.5 million in fiscal 2022 [39] Company Strategy and Development Direction - The company is focused on profitable and stable growth moving into fiscal 2024, with strategic actions aimed at optimizing operations and increasing gross margins [26][74] - The launch of Express Genes is expected to enhance contribution margins and expand market opportunities [56][58] - The company aims to leverage its investments in the Wilsonville facility to drive future growth and profitability [27][74] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery in Biopharma revenue, indicating that Q4 2023 may represent the low point for this segment [32] - The company is focused on scaling Express Genes and managing costs while continuing to grow revenue and expand gross margins [74][90] - Management acknowledged macroeconomic challenges but emphasized the differentiated product offerings that position the company favorably in the market [119][120] Other Important Information - The company ended fiscal 2023 with approximately $336 million in cash and investments, down from $39 million in inventory at the end of fiscal 2022 [42][64] - Operating expenses for fiscal 2023 decreased to approximately $306.8 million from $319 million in fiscal 2022 [40] Q&A Session Summary Question: Can you talk about how much of the guidance implies or bakes in the Fast Genes? - Management indicated that the guidance reflects expectations for Express Genes and its impact on margins [51] Question: What feedback are you getting for Express Genes? - Management noted positive feedback from a mix of large pharma, small pharma, and academic customers, with a focus on existing customers for initial uptake [53][55] Question: Can you provide insight on the current penetration of the makers market? - The company estimates the makers market to be a $1.4 billion opportunity, with current penetration being minimal but with significant potential for growth through Express Genes [85] Question: What are the expectations for data storage spending in fiscal 2024? - Data storage operating expenses are expected to be in the range of $37 million to $39 million for the year [123] Question: How should we think about adjusted EBITDA loss for Biopharma for the year? - Management indicated that the focus is on achieving adjusted EBITDA breakeven for Biopharma, NGS, and SynBio as quickly as possible [124]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Twist Bioscience Corporation (NASDAQ:TWST) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - CFO Conference Call Participants Vijay Kumar - Evercore ISI Matt Sykes - Goldman Sachs Puneet Souda - Leerink Partners Luke Sergott - Barclays Steven Mah - TD Cowen Catherine Schulte - Baird Rachel Vatnsdal - JP Morgan Matt Larew - William Blair Sung-Ji Nam - Scotiabank Operator ...

ACTACCATCAT Financial Results . BIOSCIENCE Welcome Angela Bitting SVP, Corporate Affairs; Chief ESG Officer Financial and Operational Performance Jim Thorburn Chief Financial Officer Q&A Session T This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and ESG Officer Emily Leproust - CEO and Co-Founder James Thorburn - CFO Conference Call Participants Vijay Kumar - Evercore ISI Matt Larew - William Blair Steven Mah - Cowen Sung-Ji Nam - Scotiabank Luke Sergott - Barclays Puneet Souda - SVB Securities Tom Peterson - Baird Rachel Vatnsdal - JPMorgan Operator Good morning, ladies and gentlemen, and w ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 (State or other jurisdict ...

Twist Bioscience Corp (NASDAQ:TWST) Q1 2023 Earnings Conference Call February 3, 2023 8:00 AM ET Company Participants Angela Bitting - Chief ESG Officer & SVP, Corporate Affairs Emily Leproust - Co-Founder, Chairman & CEO James Thorburn - CFO Conference Call Participants Poon Mah - Cowen and Company Luke Sergott - Barclays Bank Matthew Larew - William Blair & Company Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Noah Burhance - JPMorgan Chase & Co. Operator Welcome to Twist Bioscience's Fiscal 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...